SLC5A2 and type 2 diabetes mellitus: No consensus was reached regarding the prescription of SGLT2 inhibitors to all patients with diabetes (regardless of ulceration status), or similarly to patients with type 2 diabetes with glycaemic control above target with/without atherosclerotic cardiovascular disease.